Oral corticosteroids for the management of acute and maintenance aquaporin-4-immunoglobulin G-positive optic neuritis: a systematic review.

BACKGROUND: Optic neuritis associated with aquaporin-4 (AQP4)-immunoglobulin G causes severe visual loss. Although high-dose intravenous methylprednisolone is the standard for acute attacks, barriers including cost and wait times can delay urgent treatment. Similarly, restricted access to high-cost biologics leads to greater reliance on oral corticosteroid maintenance. Therefore, establishing the efficacy of accessible oral steroids is critical to more equitable health care systems. METHODS: Studies of any design reporting outcomes of oral corticosteroid treatment for acute or maintenance therapy in seropositive AQP4-neuromyelitis optica spectrum disorder optic neuritis were included. Medline, Embase, Web of Science, PubMed, Scopus, and Cochrane CENTRAL were searched from inception to July 10, 2025. RESULTS: Thirty-two studies were included (5 acute treatment, 27 maintenance treatment), comprising case reports, case series, and retrospective cohorts. In the acute setting (n = 5 studies), high-dose oral methylprednisolone (1 g/day) was associated with visual recovery, whereas low-dose prednisone monotherapy (e.g., 20 mg/day) resulted in incomplete recovery and early relapse. In the maintenance setting (n = 27 studies), oral corticosteroid monotherapy was associated with high rates of treatment relapse, particularly in pediatric cohorts. Successful tapering was observed primarily when oral steroids were used as a bridge to steroid-sparing immunosuppressants rather than as a standalone long-term strategy. CONCLUSIONS: High-dose oral methylprednisolone is likely a practical and effective alternative to intravenous therapy for acute AQP4-positive optic neuritis, especially in resource-limited settings. Conversely, low-dose oral monotherapy is insufficient for acute rescue or long-term disease control. Clinical management should prioritise high-dose regimens for acute treatment and restrict maintenance steroids to a bridging role during initiation of steroid-sparing agents.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-14
DOI
https://doi.org/10.1016/j.jcjo.2026.10.007
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oral corticosteroids for the management of acute and maintenance aquaporin-4-immunoglobulin G-positive optic neuritis: a systematic review.

Jonathan Andrew Micieli, Afreen Ahmad, Aljeena Qureshi
PubMed
Multiple Sclerosis Research Studies
article

Oral corticosteroids for the management of acute and maintenance aquaporin-4-immunoglobulin G-positive optic neuritis: a systematic review.

Jonathan Andrew Micieli, Afreen Ahmad, Aljeena Qureshi
article en

Abstract

BACKGROUND: Optic neuritis associated with aquaporin-4 (AQP4)-immunoglobulin G causes severe visual loss. Although high-dose intravenous methylprednisolone is the standard for acute attacks, barriers including cost and wait times can delay urgent treatment. Similarly, restricted access to high-cost biologics leads to greater reliance on oral corticosteroid maintenance. Therefore, establishing the efficacy of accessible oral steroids is critical to more equitable health care systems. METHODS: Studies of any design reporting outcomes of oral corticosteroid treatment for acute or maintenance therapy in seropositive AQP4-neuromyelitis optica spectrum disorder optic neuritis were included. Medline, Embase, Web of Science, PubMed, Scopus, and Cochrane CENTRAL were searched from inception to July 10, 2025. RESULTS: Thirty-two studies were included (5 acute treatment, 27 maintenance treatment), comprising case reports, case series, and retrospective cohorts. In the acute setting (n = 5 studies), high-dose oral methylprednisolone (1 g/day) was associated with visual recovery, whereas low-dose prednisone monotherapy (e.g., 20 mg/day) resulted in incomplete recovery and early relapse. In the maintenance setting (n = 27 studies), oral corticosteroid monotherapy was associated with high rates of treatment relapse, particularly in pediatric cohorts. Successful tapering was observed primarily when oral steroids were used as a bridge to steroid-sparing immunosuppressants rather than as a standalone long-term strategy. CONCLUSIONS: High-dose oral methylprednisolone is likely a practical and effective alternative to intravenous therapy for acute AQP4-positive optic neuritis, especially in resource-limited settings. Conversely, low-dose oral monotherapy is insufficient for acute rescue or long-term disease control. Clinical management should prioritise high-dose regimens for acute treatment and restrict maintenance steroids to a bridging role during initiation of steroid-sparing agents.

PubMed
University of Toronto (CA), McMaster University (CA)
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon